Iran J Radiol. 2020 October; 17(4):e101725.

Published online 2020 October 21.

Case Report



Primary Thymic Mucinous Adenocarcinoma: A Case Report Focusing on Radiological Findings and Review of the Literature

Young Hoon Koo¹, Jae Wook Lee^{1,*}, Jai Soung Park¹, Kyung Eun Shin¹, Heon Lee¹ and Susie Chin²

¹Department of Radiology, Soonchunhyang University Hospital Bucheon, Bucheon, South Korea ²Department of Pathology, Soonchunhyang University Hospital Bucheon, Bucheon, South Korea

corresponding author: Department of Radiology, Soonchunhyang University Hospital Bucheon, Bucheon, South Korea. Tel: +82-326216823, Email: ljw2000e@naver.com

Received 2020 February 22; Revised 2020 July 04; Accepted 2020 August 23.

Abstract

Primary thymic mucinous adenocarcinoma is a very rare disease. Its clinical findings are not well known. Its prognosis is poor. We present a case of primary thymic mucinous adenocarcinoma in a 60-year-old woman. The patient visited the emergency room with dysarthria as a chief complaint, and a mass was found in the occipital bone and petrous apex in brain computed tomography (CT) and magnetic resonance imaging (MRI). The lesion was considered metastasis, and body CT evaluation was performed to find the primary origin. In CT, a large peripheral enhancing mass with central low attenuation and calcification was found in the anterior mediastinum. Pathologic confirmation of the anterior mediastinal mass was done by percutaneous needle biopsy procedure. The patient was diagnosed with primary thymic mucinous adenocarcinoma. We also reviewed and analyzed previous literature focusing on radiologic findings. The possibility of primary thymic mucinous adenocarcinoma should be considered if a large mass with a heterogeneous enhancement pattern is accompanied by adjacent tissue involvement, associated thymic cyst, or calcification.

Keywords: Calcification, Radiological Findings, Thymic Mucinous Adenocarcinoma, Thymic Cyst

1. Introduction

Primary thymic adenocarcinoma is a rare disease. Although the incidence varies according to literature, it accounts for about 1.6% to 3.98% of thymic carcinomas (1, 2). Mucinous adenocarcinoma is one of its subtypes. So far, 27 cases have been published in the English literature.

Due to the rarity of the disease, clinical findings are not well known. Previous studies have mainly reported its pathological findings. Few reports have focused on imaging findings. The known computed tomography findings are a large anterior mediastinal mass with cystic change and invading adjacent major vessels (3-5).

Among thymic adenocarcinomas, the prognosis for the mucinous subtype is poor (6). According to previous literature, patients undergoing complete resection may survive for more than 5 years. In many patients, however, adjacent tissue infiltration is observed at the time of diagnosis and that leads to poor prognosis (7).

We present a case of a primary thymic mucinous adenocarcinoma patient with radiological and pathological findings. We also reviewed and analyzed previous literature focusing on radiologic findings of primary thymic mucinous adenocarcinoma. In addition, we analyzed magnetic resonance imaging (MRI) findings that were rarely introduced in the previous literature, and tried to find imaging findings that could help diagnose this disease.

2. Case Presentation

A 60-year-old woman visited the emergency room due to dysarthria for 10 days. The patient had no notable medical history except for hypertension. On physical examination, the patient's tongue deviated to the left. Brain computed tomography (CT) scan and MRI with contrast enhancement (CE) were performed to identify the cause of dysarthria. On CT scan, an osteolytic lesion of about 2.5 cm in size was found in the left lateral part of the occipital bone and petrous apex (Figure 1A). The lesion showed homogeneous enhancement in CE MRI (Figure 1B). Diffusion weighted imaging (DWI) showed high signal intensity (SI) and low apparent diffusion coefficient (ADC) values. The first differential diagnosis was metastasis. The other differential diagnosis was primary solid malignant tumor. Except for the above findings, no abnormalities were found in the brain parenchyma or blood vessels.

To find the primary lesion, the patient underwent additional chest and abdominal CT with CE and positron emis-

Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.



Figure 1. A 60-year-old woman with primary thymic mucinous adenocarcinoma presented with dysarthria due to metastasis to the skull base. A, In the brain CT with bone window setting, an osteolytic lesion (arrowhead) of about 2.5 cm in size is observed in the left lateral part of the occipital bone and petrous apex, and this lesion is invading the left hypoglossal canal (arrow). B, In contrast-enhanced (CE) brain MRI, there was approximately 2.5 cm homogeneous enhancing lesion in the left lateral part of occipital bone and petrous apex, invading the left hypoglossal canal (arrow). C, A heterogeneous enhancing mass of about 6.9 cm was observed in CE Chest CT, with central low attenuation and focal calcification. D-E, Chest MRI showed that this mass had a heterogeneous high signal intensity in the T2-weighted image (D), heterogeneous enhancement in the CE T1-weighted image, and invasion of adjacent superior vena cava and both innominate veins. F, The peripheral portion of this mass shows a low apparent diffusion coefficient value.

sion tomography-CT (PET-CT). Abdominal CT revealed no evidence of primary tumor. However, chest CT revealed a mass of about 6.9 \times 6.4 \times 4.9 cm in size in the anterior mediastinum. The mass showed enhancement in the periphery of the lesion, low attenuation in the center, and focal calcification. The mass was in close contact with the adjacent superior vena cava (SVC) and the left innominate vein. Invasion was suspected due to irregularity of the margin (Figure 1C). The first differential diagnosis was invasive thymoma, considering that a large tumor could be seen as a heterogeneous mass due to cystic or necrotic degeneration. In addition, calcification might be present throughout a tumor. Another differential diagnosis was thymic carcinoma. This is because thymic carcinoma is more likely to metastasize than invasive thymoma and invade adjacent structures. It may contain calcification in a large size of tumor. Another differential diagnosis was thymic germ cell tumor due to combination of soft tissue and calcification. PET-CT showed no abnormalities except for an avid 18F fluorodeoxyglucose (FDG) uptake in the mass and a nodule observed in the anterior mediastinum and skull base, respectively.

To diagnose mediastinal mass, the patient underwent

percutaneous needle biopsy procedure. Pathological findings showed that nests and clusters of atypical tumor cells floated in the extracellular mucus pool. Immunohistochemical staining revealed strong immunoreactivity for cytokeratin (CK) 7, CK20, and CDX2 (Figure 2). The pathologic diagnosis was mucinous adenocarcinoma. Thyroid transcription factor-1 (TTF-1) was negative.

Chest CE MRI was performed to evaluate resectability before surgery. A mass with intermediate SI in TI-weighted image (TIWI), heterogeneous high SI in T2-weighted image, and heterogeneous enhancement in contrast-enhanced TIWI was observed in the anterior mediastinum. In the DWI, the peripheral portion of the lesion showed high SI and low ADC value. Dark SI in the mass was observed. It correlated with calcification seen in CT. The mass showed irregular boundaries with SVC and both innominate veins, suggesting invasion (Figure 1D and F).

Surgical findings revealed an irregular, hard mass in the anterior mediastinum with invasion of the pericardium, left innominate vein, and SVC. Although surgical resection was attempted as much as possible, complete resection was not possible due to severe adhesion of SVC. Surgical tissue was also diagnosed as mucinous adenocarci-



Figure 2. A, Microscopic findings of the anterior mediastinal mass. Hematoxylin and eosin (H & E) staining reveals nests and clusters of atypical tumor cells float in pools of extracellular mucin (H & E, 40 ×). B-D, Immunohistochemical stains reveal strong immunoreactivity for CK7, CK20 and CDX2 (100 ×).

noma. Invasion was observed in mediastinal fats around the mass. Finally, the patient was diagnosed with primary thymic mucinous adenocarcinoma.

The patient underwent adjuvant radiotherapy in the mediastinal area after surgery and steroid and fractionated stereotactic radiotherapy for metastatic lesions of the skull base. Postoperatively, the patient continued chemotherapy. However, metastases were found in the sternum and ribs in the bone scan performed 4 months after surgery. Multiple metastatic lung nodules were developed in chest CT. The skull base lesion did not change. One year after the surgery, metastases progressed despite continued chemotherapy.

3. Discussion

Primary thymic carcinoma accounts for 14.1% of thymic epithelial tumors. It has more than 10 subtypes (8). Although there are some differences according to race and geography, squamous cell carcinoma is the most common, accounting for about 61.8% - 84.07% and thymic adenocarcinoma is relatively rare, accounting for 1.6% - 3.98% of all cases of primary thymic carcinomas (1, 2, 8). According to the World Health Organization (WHO) classification, thymic adenocarcinoma can be divided into four subtypes: papillary adenocarcinoma, thymic carcinoma with adenoid cystic carcinoma-like features, mucinous adenocarcinoma, and not otherwise specified (NOS) (9). Mucinous adenocarcinoma is a rare subtype. It was first reported by Choi et al. (10) in 2003. To date, 27 cases of mucinous adenocarcinoma have been reported in the English literature.

Patients with primary thymic mucinous adenocarcinoma most commonly complain of respiratory symptoms such as coughing and dyspnea. Sometimes, they have chest pain or dysphagia (7). However, symptoms of patients with primary thymic mucinous adenocarcinoma are often nonspecific. For this reason, it is difficult to diagnose primary thymic mucinous adenocarcinoma based on clinical findings. Radiologic imaging findings are helpful for its diagnosis. Our patient had no respiratory symptoms but showed dysarthria, and a physical examination revealed the left-sided deviation of the tongue. This was thought to be the result of the metastatic mass in the occipital bone and petrous apex invading the left hypoglossal canal.

Up to date, there were very few radiologic reviews of primary thymic mucinous adenocarcinoma. Most cases of primary thymic mucinous adenocarcinoma are reported in pathology journals. CT figures and descriptions were found in 11 of 27 cases reported in the English literature (3-7, 11-16). We analyzed a total of 12 cases of CT images, including the previous 11 cases and our case. Information that could not be identified with a given CT image such as tumor size or component was analyzed based on the description shown in the literature. We classified CT images by tumor composition (solid predominancy: > 50% of solid portion; cystic predominancy: > 50% of cystic portion), enhancement pattern (homogeneous or heterogeneous), presence of calcification, and adjacent invasion (present or not).

For a total of 12 cases, their mean age was 59 years (range, 28 - 79 years). The male-to-female ratio was 1: 2 (4 men and 8 women). The average maximal diameter of tumor was 9.2 cm (range, 5.6 - 14.5 cm). Eight (67%) of these 12 cases showed solid predominancy while four (33%) cases showed cystic predominancy. All (100%) tumors had a heterogeneous enhancement pattern. No calcification was observed in seven (58%) cases. Calcification was observed in five (42%) cases. Adjacent tissue invasion was observed in seven (58%) cases at the time of diagnosis. It was not observed in five (42%) cases. The association between thymic mucinous adenocarcinoma and thymic cyst has been observed in several reports (4-6, 9, 10, 17-19). Thymic cyst was identified in six (50%) of 12 cases. Clinical and radiologic findings of these 12 cases of primary thymic mucinous adenocarcinoma are shown in Table 1.

MRI findings were rarely described in previous literature. In our patients, there was an intermediate SI in the TI-weighted image and a heterogeneous high SI in the T2-weighted image, which were similar to SI of the mucinous component of mucinous adenocarcinoma occurring in the abdomen or pelvic cavity. This correlated with the low attenuation area observed in CT. However, this finding is not specific for mucin. So more research is needed on the findings of MRI images, including image-pathology correlation.

Histologically, primary thymic mucinous adenocarcinoma has malignant tumor cells in nests, tubules, and cribriform structures floated in pools of extracellular mucin (4). Immunohistochemical staining is important for determining the origin of the tumor and for distinguishing it from thymic mucinous adenocarcinoma and other thymic carcinomas. CD5 is a widely known thymic origin marker. About 70% of thymic carcinomas are positive for CD5 (11). CK7, CK20, and CDX-2 are useful markers for distinguishing mucinous and other subtypes of thymic carcinoma (5). However, they cannot distinguish between primary and metastatic lesions. They are also positive in tumors of pulmonary, gastrointestinal tract, and ovary origins. MUC (Mucin) family proteins are evaluated as markers for thymic mucinous adenocarcinoma in limited studies. In addition, markers such as TTF-1 can be used. TTF-1 is a primary pulmonary adenocarcinoma-specific marker. It is negative in thymic tumors. Our case showed positive staining for CDX2, CK7, CK20, and MUC2, indicating mucinous type of tumor. Our case showed negative staining for TTF-1, meaning that the tumor was not of pulmonary origin.

Primary thymic mucinous adenocarcinoma has a poor prognosis, similar to thymic carcinoma. Although there is no absolute guideline for treating primary thymic mucinous adenocarcinoma, surgical resection is usually performed in the absence of adjacent tissue infiltration or insignificant adjacent tissue infiltration without distant metastasis. Although it has been reported that patients without adjacent tissue invasion can survive more than 5 years after surgical resection, many patients require additional chemotherapy and radiotherapy after surgery due to infiltration into adjacent tissues at the time of diagnosis (7). In case of severe infiltration into adjacent tissues and metastatic lesions, palliative chemotherapy is used. With incomplete resection or palliative treatment, the prognosis is known to be very poor (7).

In conclusion, although primary thymic mucinous adenocarcinoma is a rare disease, it should be considered if a large mass with a heterogeneous enhancement pattern is accompanied by adjacent tissue involvement, associated thymic cyst, or calcification. Histologically abundant extracellular mucins and immunohistochemical stains are important for its diagnosis. The prognosis differs depending on whether complete resection is possible. In general, the prognosis is poor. Therefore, early diagnosis is important. Further studies on radiology findings including MRI findings are needed.

Footnotes

Authors' Contributions: Younghoon Koo reviewed the literature and prepared the radiological images and the manuscript. Jae Wook Lee contributed to the basic study concept and design of the report and proofread the manuscript. Jai Soung Park, Kyung Eun Shin, and Heon Lee supervised and reviewed the manuscript. Susie Chin were responsible for technical and material support. All authors have read and approved the final version of the manuscript.

		, 1						
Case	Age/sex	Size, cm	CT findings					Prognosis
			Composition	Enhancement	Calcification	Thymic cyst	Adjacent invasion	1105110313
1) Takahashi et al. (11)	59/M	> 10	Solid	Heterogeneous	-	-	-	DOD after 11 mon
2) Ra et al. (3)	82/F	14.5	Cystic	Heterogeneous	-	+	+(aortic arch)	Passed away from complications of surgery
3) Seki et al. (12)	49/M	8.5	Solid	Heterogeneous	+	-	+ (pericardium, left innominate vein)	Recurrence (pleural dis- semination) AWD for 11 mon
4) Maeda et al. (4)	52/F	7.5	Solid	Heterogeneous		+	+(sternum)	Recurrence (lung, cervical LN) AWD for 11 mon
5) Seon et al. (13)	66/F	12.6	Cystic	Heterogeneous	+	+	-	AWD for 60 mon
6) Abdul-Ghafar et al. (5)	36/F	5.6	Cystic	Heterogeneous	-	+	-	Recurrence (lung, pleural dissemina- tion) DOD after 15 mon
7) Maghbool et al. (6)	28/F	-	Solid	Heterogeneous	-	+	+ (pericardium)	AWD for 30 mon
8) Lee et al. (14)	31/M	11.9	Solid	Heterogeneous	+		-	
9) Sakanoue et al. (15)	39/F	6.5	Solid	Heterogeneous	-	+	+ (pericardium, left innominate vein)	
10) Kinoshita et al. (7)	79/F	7	Cystic	Heterogeneous	+	-	-	AWD for 14 mon
11) Liu et al. (16)	50/M	10	Solid	Heterogeneous		-	+(superior vena cava)	DOD after 3.5 mon
12) Current case	60/F	6.9	Solid	Heterogeneous	+	-	+(superior vena cava, left innominate vein)	AWD for 15 mon

Table 1. Clinical and Radiologic Findings of 12 Reported Primary Thymic Mucinous Adenocarscinomas

Abbreviations: AWD, alive with the disease; DOD, dead because of the disease; F, female; M, male; mon, months.

Conflict of Interests: The authors declare that there are no conflict of interests.

Ethical Approval: IRB file number is SCHBC 2020-02-002-001.

Funding/Support: This paper was partially supported by Soonchunhyang University research funds.

Informed Consent: The patient provided a written informed consent for the publication of this report.

References

1. Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, et

al. Thymic carcinoma outcomes and prognosis: results of an international analysis. *J Thorac Cardiovasc Surg*. 2015;**149**(1):95–100. 101 e1-2. doi:10.1016/j.jtcvs.2014.09.124. [PubMed: 25524678].

- Kwon AY, Han J, Chu J, Choi YS, Jeong BH, Ahn MJ, et al. Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature. *Pathol Res Pract.* 2017;213(2):106–12. doi: 10.1016/j.prp.2016.11.012. [PubMed: 28038793].
- Ra SH, Fishbein MC, Baruch-Oren T, Shintaku P, Apple SK, Cameron RB, et al. Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature. *Am J Surg Pathol*. 2007;**31**(9):1330–6. doi: 10.1097/PAS.0b013e31802f72ef. [PubMed: 17721187].
- Maeda D, Ota S, Ikeda S, Kawano R, Hata E, Nakajima J, et al. Mucinous adenocarcinoma of the thymus: a distinct variant of thymic carcinoma. *Lung Cancer.* 2009;64(1):22–7. doi: 10.1016/j.lungcan.2008.06.019. [PubMed: 18722686].

- Abdul-Ghafar J, Yong SJ, Kwon W, Park IH, Jung SH. Primary thymic mucinous adenocarcinoma: a case report. *Korean J Pathol*. 2012;46(4):377–81. doi: 10.4132/KoreanJPathol.2012.46.4.377. [PubMed: 23110032]. [PubMed Central: PMC3479823].
- Maghbool M, Ramzi M, Nagel I, Bejarano P, Siebert R, Saeedzadeh A, et al. Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature. *BMC Clin Pathol.* 2013;13(1):17. doi: 10.1186/1472-6890-13-17. [PubMed: 23725376]. [PubMed Central: PMC3672093].
- Kinoshita F, Shoji F, Takada K, Toyokawa G, Okamoto T, Yano T, et al. Mucinous adenocarcinoma of the thymus: report of a case. *Gen Thorac Cardiovasc Surg.* 2018;66(2):111–5. doi: 10.1007/s11748-017-0781-1. [PubMed: 28474330].
- 8. Kondo K, Monden Y. A questionnaire about thymic epithelial tumors in Japan. *JJapan Associat Chest Surg.* 2001;**15**(6):633–42. doi: 10.2995/jacsurg.15.633.
- 9. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. *J Thorac Oncol*. 2015;**10**(9):1240–2.
- Choi WW, Lui YH, Lau WH, Crowley P, Khan A, Chan JK. Adenocarcinoma of the thymus: report of two cases, including a previously undescribed mucinous subtype. *Am J Surg Pathol*. 2003;**27**(1):124–30. doi: 10.1097/00000478-200301000-00014. [PubMed: 12502935].
- Takahashi F, Tsuta K, Matsuno Y, Takahashi K, Toba M, Sato K, et al. Adenocarcinoma of the thymus: mucinous subtype. *Hum Pathol.* 2005;**36**(2):219–23. doi: 10.1016/j.humpath.2004.11.008. [PubMed: 15754301].
- Seki E, Aoyama K, Ueda M, Haga T, Nakazato Y, Iijima M, et al. Mucinous adenocarcinoma of the thymus: a case report. J Thorac Oncol. 2008;3(8):935–7. doi: 10.1097/JTO.0b013e3181803eee. [PubMed:

18670316].

- Seon HJ, Kim KH, Choi YD, Song SY, Yoon HJ, Kim YH, et al. Angina pectoris caused by the extrinsic compression of coronary artery by primary thymic mucinous adenocarcinoma. *Int J Cardiol.* 2012;**156**(1):e13– 5. doi: 10.1016/j.ijcard.2011.07.100. [PubMed: 21856024].
- Lee Y, Park S, Lee SH, Lee H. Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma. *BMC Cancer*. 2017;**17**(1):330. doi: 10.1186/s12885-017-3282-9. [PubMed: 28506304]. [PubMed Central: PMC5432996].
- Sakanoue I, Hamakawa H, Fujimoto D, Imai Y, Minami K, Tomii K, et al. KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. *J Thorac Dis.* 2017;9(8):E694–7. doi: 10.21037/jtd.2017.07.11. [PubMed: 28932588]. [PubMed Central: PMC5594120].
- Liu HW, Liu CY, Yeh YC. Disseminated and massive tumor burden in a case of primary thymic mucinous adenocarcinoma. J Cancer Res Practice. 2019;6(3):151.
- Moser B, Schiefer AI, Janik S, Marx A, Prosch H, Pohl W, et al. Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. *Am J Surg Pathol*. 2015;**39**(4):541– 8. doi: 10.1097/PAS.00000000000359. [PubMed: 25517960].
- Akiba J, Harada H, Yokoyama S, Hashiguchi T, Kawahara A, Mitsuoka M, et al. Mucinous cystic tumor with CK20 and CDX2 expression of the thymus: Is this a benign counterpart of adenocarcinoma of the thymus, enteric type? *Pathol Int*. 2016;**66**(1):29–33. doi: 10.1111/pin.12361. [PubMed: 26581569].
- Kapur P, Rakheja D, Bastasch M, Molberg KH, Sarode VR. Primary mucinous adenocarcinoma of the thymus: a case report and review of the literature. Arch Pathol Lab Med. 2006;130(2):201–4. doi: 10.1043/1543-2165(2006)130[201:PMAOTT]2.0.CO;2. [PubMed: 16454563].